Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

July 1, 2024

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury

Jia Liu, Ranyi Luo, Yinhao Zhang, et al.

Clin Mol Hepatol. 2024;30(4):585-619.

Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient...

Review

July 11, 2024

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

Mengyao Yan, Shuli Man, Long Ma, et al.

Clin Mol Hepatol. 2024;30(4):620-648.

Steatotic liver diseases (SLD) are the principal worldwide cause of cirrhosis and end-stage liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic dysfunction-associated alcoholic liver disease...

Original Article

May 29, 2024

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, et al.

Clin Mol Hepatol. 2024;30(4):735-755.

Background/Aims: Hepatitis B virus (HBV)-DNA integration in HBV-related hepatocellular carcinoma (HBV-HCC) can be targeted by HBV-specific T cells. SCG101 is an autologous, HBV-specific T-cell product expressing a T-cell receptor (TCR)...

Original Article

June 24, 2024

Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023

Donghee Kim, Richie Manikat, Karn Wijarnpreecha, et al.

Clin Mol Hepatol. 2024;30(4):756-770.

Backgrounds/Aims: The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based...

Original Article

June 25, 2024

UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL

Renyu Zhang, Can Li, Shuai Zhang, et al.

Clin Mol Hepatol. 2024;30(4):771-792.

Background/Aims: Ubiquitination is widely involved in the progression of hepatocellular carcinoma (HCC) by regulating various cellular processes. However, systematic strategies for screening core ubiquitin-related genes, clarifying their functions and mechanisms,...

Original Article

July 19, 2024

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, et al.

Clin Mol Hepatol. 2024;30(4):793-806.

Background/Aims: Serum hepatitis B virus (HBV) DNA levels and non-invasive liver fibrosis scores are significantly associated with hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. Nonetheless, the relationship...

Original Article

July 23, 2024

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, et al.

Clin Mol Hepatol. 2024;30(4):807-823.

Background/Aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response...

Original Article

July 25, 2024

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, et al.

Clin Mol Hepatol. 2024;30(4):824-844.

Background/Aims: Blocking the complement system is a promising strategy to impede the progression of metabolic dysfunction–associated steatotic liver disease (MASLD). However, the interplay between complement and MASLD remains to be...

Original Article

July 25, 2024

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, et al.

Clin Mol Hepatol. 2024;30(4):845-862.

Background/Aims: Shifts in the gut microbiota and metabolites are interrelated with liver cirrhosis progression and complications. However, causal relationships have not been evaluated comprehensively. Here, we identified complication-dependent gut microbiota...

Original Article

July 26, 2024

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD

Baokai Sun, Xiaoqian Ding, Jie Tan, et al.

Clin Mol Hepatol. 2024;30(4):863-882.

Backgrounds/Aims: Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of...

Original Article

July 29, 2024

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

Chung-Feng Huang, Chia-Yen Dai, Yi-Hung Lin, et al.

Clin Mol Hepatol. 2024;30(4):883-894.

Background/Aims: Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to...

Original Article

August 5, 2024

KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression

Young Hoon Jung, Yun Ji Lee, Tam Dao, et al.

Clin Mol Hepatol. 2024;30(4):895-913.

Background/Aims: Potassium channel tetramerization domain containing 17 (KCTD17) protein, an adaptor for the cullin3 (Cul3) ubiquitin ligase complex, has been implicated in various human diseases; however, its role in hepatocellular...

Original Article

August 6, 2024

Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma

Yu-Hang Ye, Hao-Yang Xin, Jia-Li Li, et al.

Clin Mol Hepatol. 2024;30(4):914-928.

Backgrounds/Aims: Intrahepatic cholangiocarcinoma (ICC) is a highly desmoplastic tumor with poor prognosis even after curative resection. We investigated the associations between the composition of the ICC stroma and immune cell...

Original Article

August 27, 2024

The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study

Keungmo Yang, Sunghwan Kim, Hyun Yang, et al.

Clin Mol Hepatol. 2024;30(4):929-942.

Background/Aims: Alcohol-associated liver disease (ALD) is a public health concern. ALD patients often have psychiatric comorbidities, but the effects of psychiatric interventions on ALD are not well-established. This study explores...

Original Article

August 29, 2024

Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK

Kwanjoo Lee, Jaeyu Park, Jinseok Lee, et al.

Clin Mol Hepatol. 2024;30(4):943-958.

Background/Aims: Considering emerging evidence on long COVID, comprehensive analyses of the post-acute complications of SARS-CoV-2 infection in the gastrointestinal and hepatobiliary systems are needed. We aimed to investigate the impact...

Current Issue: Volume 30(4); Oct 2024

Review

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury

Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(4):585-619. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0222

View: 2172 Download: 254

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao

Clin Mol Hepatol. 2024;30(4):620-648. Published online July 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0315

View: 1917 Download: 212 Web of Science: 1 Crossref: 2

Editorial

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):649-652. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0558

View: 1308 Download: 75 Web of Science: 2 Crossref: 2

Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”

Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):653-655. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0482

View: 1009 Download: 55

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):656-658. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0499

View: 780 Download: 29 Crossref: 2

Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon

Clin Mol Hepatol. 2024;30(4):659-662. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0516

View: 927 Download: 74

Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”

Eun Ju Cho

Clin Mol Hepatol. 2024;30(4):663-664. Published online July 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0557

View: 731 Download: 33 Web of Science: 1 Crossref: 1

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):665-668. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0562

View: 911 Download: 79 Web of Science: 2 Crossref: 2

Deep learning assisted biomarker development in patients with chronic hepatitis B: Editorial on “Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection”

Yong Eun Chung

Clin Mol Hepatol. 2024;30(4):669-672. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0563

View: 917 Download: 34

Unlocking the role of liver sinusoidal endothelial cells: Key players in liver fibrosis: Editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”

Yasuko Iwakiri

Clin Mol Hepatol. 2024;30(4):673-676. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0343

View: 1152 Download: 91 Crossref: 1

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Seren M. Gedallovich, Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):677-681. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0418

View: 1003 Download: 27

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Naoshi Nishida

Clin Mol Hepatol. 2024;30(4):682-688. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0324

View: 1023 Download: 89 Crossref: 1

Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Joseph C. Ahn, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):689-691. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0348

View: 1013 Download: 25 Crossref: 1

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

Hae Lim Lee, Jeong Won Jang

Clin Mol Hepatol. 2024;30(4):692-694. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0346

View: 907 Download: 41

Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”

Simone Incicco, Salvatore Piano

Clin Mol Hepatol. 2024;30(4):695-697. Published online June 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0409

View: 994 Download: 22 Web of Science: 1 Crossref: 1

Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Junlong Dai, Jimmy Che-To Lai, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2024;30(4):698-701. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0327

View: 994 Download: 43 Crossref: 1

The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts”

Ho Joong Choi

Clin Mol Hepatol. 2024;30(4):702-704. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0426

View: 868 Download: 35

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 1294 Download: 52 Web of Science: 1 Crossref: 2

Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

So Jung Kim, Jeongeun Hyun

Clin Mol Hepatol. 2024;30(4):709-713. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0412

View: 1309 Download: 70 Web of Science: 1 Crossref: 2

Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):714-717. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0425

View: 1055 Download: 43 Web of Science: 1 Crossref: 1

Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study”

Yewan Park, Dong Hyun Sinn

Clin Mol Hepatol. 2024;30(4):718-720. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0519

View: 824 Download: 60

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Junjie Yu

Clin Mol Hepatol. 2024;30(4):721-723. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0443

View: 998 Download: 47 Web of Science: 1

Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):724-727. Published online July 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0465

View: 1024 Download: 56 Web of Science: 1 Crossref: 1

Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2024;30(4):728-734. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0469

View: 1144 Download: 63 Web of Science: 1

Original Article

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 2097 Download: 242 Crossref: 2

Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023

Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):756-770. Published online June 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0318

View: 1559 Download: 83

UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL

Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu, Dong Wu, Tianjiao Zhang, Haijiao Yang, Ding Wei, Zhinan Chen, Huijie Bian

Clin Mol Hepatol. 2024;30(4):771-792. Published online June 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0236

View: 1605 Download: 256

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

Clin Mol Hepatol. 2024;30(4):793-806. Published online July 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0252

View: 1744 Download: 167 Web of Science: 1 Crossref: 1

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 1957 Download: 251 Web of Science: 1 Crossref: 2

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

Clin Mol Hepatol. 2024;30(4):824-844. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229

View: 1646 Download: 260

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Clin Mol Hepatol. 2024;30(4):845-862. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349

View: 3624 Download: 929 Crossref: 2

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD

Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang

Clin Mol Hepatol. 2024;30(4):863-882. Published online July 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0268

View: 1433 Download: 210

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

Chung-Feng Huang, Chia-Yen Dai, Yi-Hung Lin, Chih-Wen Wang, Tyng-Yuan Jang, Po-Cheng Liang, Tzu-Chun Lin, Pei-Chien Tsai, Yu-Ju Wei, Ming-Lun Yeh, Ming-Yen Hsieh, Chao-Kuan Huang, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):883-894. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0414

View: 1079 Download: 88

KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression

Young Hoon Jung, Yun Ji Lee, Tam Dao, Kyung Hee Jung, Junjie Yu, Ah-Reum Oh, Yelin Jeong, HyunJoon Gi, Young Un Kim, Dongryeol Ryu, Michele Carrer, Utpal B. Pajvani, Sang Bae Lee, Soon-Sun Hong, KyeongJin Kim

Clin Mol Hepatol. 2024;30(4):895-913. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0364

View: 1587 Download: 252

Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma

Yu-Hang Ye, Hao-Yang Xin, Jia-Li Li, Ning Li, Si-Yuan Pan, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Peng-Cheng Wang, Chu-Bin Luo, Rong-Qi Sun, Jia Fan, Jian Zhou, Zheng-Jun Zhou, Shao-Lai Zhou

Clin Mol Hepatol. 2024;30(4):914-928. Published online August 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0296

View: 1322 Download: 160 Crossref: 1

The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study

Keungmo Yang, Sunghwan Kim, Hyun Yang, Sheng-Min Wang, Bumseok Jeong, Hyun Kook Lim, Si Hyun Bae

Clin Mol Hepatol. 2024;30(4):929-942. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0278

View: 1090 Download: 102

Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK

Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Myeongcheol Lee, Hyeon Jin Kim, Yejun Son, Sang Youl Rhee, Lee Smith, Masoud Rahmati, Jiseung Kang, Hayeon Lee, Yeonjung Ha, Dong Keon Yon

Clin Mol Hepatol. 2024;30(4):943-958. Published online August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0203

View: 1416 Download: 112 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):959-961. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233

View: 1118 Download: 61 Crossref: 2

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 1172 Download: 94 Crossref: 3

Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):965-969. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0386

View: 1454 Download: 76

Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”

Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2024;30(4):970-973. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0280

View: 1045 Download: 51

Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):974-977. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0417

View: 1210 Download: 68

Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau

Clin Mol Hepatol. 2024;30(4):978-981. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0565

View: 751 Download: 47

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 791 Download: 49

Correspondence

Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(4):987-988. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0266

View: 1082 Download: 34

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2024;30(4):989-991. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0705

View: 638 Download: 28 Crossref: 1

Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”

Haeryoung Kim, Dong Ho Lee, Yoon Jung Hwang

Clin Mol Hepatol. 2024;30(4):992-993. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0624

View: 683 Download: 31 Crossref: 1

Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong

Clin Mol Hepatol. 2024;30(4):994-996. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0552

View: 793 Download: 26 Web of Science: 1 Crossref: 1

Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2024;30(4):997-999. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0588

View: 667 Download: 29

Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Vy H. Nguyen, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(4):1000-1001. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0611

View: 664 Download: 34

Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”

Jiaorong Qu, Le Wang, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(4):1002-1004. Published online May 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0357

View: 1038 Download: 47

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(4):1005-1008. Published online May 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0394

View: 1133 Download: 55

Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Su Bin Lim, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(4):1009-1011. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0368

View: 986 Download: 55 Crossref: 1

Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”

Do Seon Song, Dong Joon Kim

Clin Mol Hepatol. 2024;30(4):1012-1015. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0448

View: 978 Download: 16

Correspondence to editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Clin Mol Hepatol. 2024;30(4):1016-1018. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0365

View: 967 Download: 31

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(4):1019-1022. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471

View: 914 Download: 55

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):1023-1025. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0472

View: 961 Download: 40 Crossref: 2

Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(4):1026-1027. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0470

View: 747 Download: 42

Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Mehrangiz Dezhbord, Kyun-Hwan Kim

Clin Mol Hepatol. 2024;30(4):1028-1030. Published online July 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0515

View: 1164 Download: 76 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”

Pin-Nan Cheng, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):1031-1032. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0228

View: 1131 Download: 41

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(4):1033-1034. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0360

View: 881 Download: 24

Reply to correspondence on “Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity”

Atsumasa Komori

Clin Mol Hepatol. 2024;30(4):1035-1036. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0242

View: 1185 Download: 34

Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):1037-1038. Published online May 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0320

View: 1106 Download: 52

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):1039-1041. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0801

View: 593 Download: 16

Reply to correspondence on “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis”

Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):1042-1043. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0685

View: 611 Download: 26 Web of Science: 1 Crossref: 1

Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):1044-1046. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0584

View: 606 Download: 20

Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):1047-1049. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0666

View: 625 Download: 51

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Seren M. Gedallovich, Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):1050-1052. Published online July 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0546

View: 809 Download: 32

Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):1053-1054. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0572

View: 1129 Download: 37 Web of Science: 1 Crossref: 1

Snapshot

Examining the therapeutic landscape of beta-blockers in portal hypertension

Anna Brujats, Càndid Villanueva

Clin Mol Hepatol. 2024;30(4):1055-1059. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0144

View: 5671 Download: 58

Erratum

Erratum to ‘Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction’ [Clin Mol Hepatol 2024;30:539-560]

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

Clin Mol Hepatol. 2024;30(4):1060-1065. Published online July 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0060e
Corrects: Clin Mol Hepatol 2024;30(3):539

View: 848 Download: 25

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

07 Days

Publication after acceptance

03 Days

*Last 12 months

Viewed By 5081	MAFLD: How is it different from NAFLD?
Viewed By 5072	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4494	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4470	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4360	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 138	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach